BazEkon - Biblioteka Główna Uniwersytetu Ekonomicznego w Krakowie

BazEkon home page

Meny główne

Autor
Kaczyński Łukasz (Aestimo s.c., Cracow, Poland), Pawlik Dariusz (Aestimo s.c., Cracow, Poland), Serafin Beata (Aestimo s.c., Cracow, Poland), Wójcik Rafał (Aestimo s.c., Cracow, Poland), Kaczor Marcin (Aestimo s.c., Cracow, Poland ; Jagiellonian University Medical College, Cracow, Poland), Lis Joanna (Sanofi-Aventis Sp. z o.o., Warsaw, Poland), Bernaszuk Ewelina (Sanofi-Aventis Sp. z o.o., Warsaw, Poland), Wepsięć Katarzyna (Sanofi-Aventis Sp. z o.o., Warsaw, Poland)
Tytuł
VaxigripTetra (Quadrivalent Influenza Vaccine) - Evidence for Clinical and Economic Benefits from Vaccination in Population Aged 65 and Over in Poland
Źródło
Journal of Health Policy and Outcomes Research, 2017, nr 2, s. 23-30, rys., tab., bibliogr. 25 poz.
Słowa kluczowe
Stan zdrowia ludności, Zdrowie, Ludzie starsi, Profilaktyka zdrowotna
Health status of the population, Health, Elderly people, Preventive health care
Uwagi
summ.
Abstrakt
Background: Vaccination is considered to be the most effective way of preventing influenza related-illnesses and their complications, which is particularly important in elderly population (aged 65+), often characterized with more rapid and severe clinical course of infection. Quadrivalent influenza vaccines (QIV) have been developed to avoid the poor antigenic match observed in the trivalent formulation vaccine (TIV). Methods: The study assess the immunogenicity, cost-effectiveness and impact on the Polish budget of inactivated quadrivalent influenza vaccine (VaxigripTetra), assuming its reimbursement in the active immunization of adults 65 years of age and older. Results: As clinical results have shown, non-inferior immunogenicity of QIV to each TIV for the shared strains and superior immunogenicity of QIV to each TIV for the alternate B strain. The inactivated QIV was well tolerated. VaxigripTetra is a highly cost-effective option compared to the strategy of "no vaccination" (ICUR=14,988 PLN/QALY - payer's + patients' perspective [PPP+P], ICUR=6,838 PLN/QALY - payers' perspective [PPP]) and also to TIV (ICUR=121,418 PLN or ICUR=114,360 PLN, respectively). The increase of the public payer's expenditures - 9.0-23.3 million PLN annually - will result in additional health effects: 1,091 - 4,805 GP visits, 175-771 hospitalizations and 74-326 deaths avoided per year. Conclusions: VaxigripTetra reimbursement could trigger a faster switch from TIVs to QIVs and at the same time could increase the vaccine coverage of the elderly population in Poland, which would lessen the ILI-related negative impact on that population at a reasonable cost to the healthcare system, while providing some savings to society.(original abstract)
Pełny tekst
Pokaż
Bibliografia
Pokaż
  1. Makowiec-Dyrda M., Tomasik T. et al.: Profilaktyka i leczenie grypy. Wytyczne Kolegium Lekarzy Rodzinnych w Polsce (2016). Available from: http://www.klrwp.pl/strona/226/profilaktyka-i-leczenie-grypy-2016/pl.
  2. Kuchar E. Prezentacja "Grypa 2017". Available from: http://www.infozdrowie.org/images/pdf/2017/13_06_2017/1_kuchar.pdf.
  3. Bekkat-Berkani R., Ray R., Jain V.K., Chandrasekaran V., Innis B.L.: Evidence update: GlaxoSmithKline's inactivated quadrivalent influenza vaccines. Expert Rev Vaccines. 2016; 15: 201-14.
  4. Grohskopf L.A., Sokolow L.Z., Broder K.R. et al.: Prevention and Control of Seasonal Influenza with Vaccines Recommendations of the Advisory Committee on Immunization Practices - United States, 2016-17 Influenza Season. MMWR Recomm Rep 2016; 65: 1-52.
  5. Harper S.A., Bradley J.S., Englund J.A. et al.: Expert Panel of the Infectious Diseases Society of America. Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48: 1003-32.
  6. European Centre for Disease Prevention and Control. Seasonal influenza vaccination in Europe. Vaccination recommendations and coverage rates in the EU Member States for eight influenza seasons: 2007-2008 to 2014-2015. Stockholm: ECDC; 2017. Available from: https://ecdc.europa.eu/sites/portal/files/documents/influenza-vaccination-2007%E2%80%932008-to-2014%E2%80%932015.pdf.
  7. Ambrose C.S., Levin M.J.: The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012; 8: 81-88.
  8. US Centers for Disease Control and Prevention. Seasonal influenza activity surveillance reports: 1999-2000 to 2010-2011 seasons. Available from: http://www.cdc.gov/flu/weekly/pastreports.htm.
  9. Toback S.L., Rothstein E., Bhatt P., Carr W., Ambrose C.S.: In-office influenza vaccination by US pediatric providers varies greatly and is higher among smaller offices. Clin Pediatr (Phila) 2012; 51: 551-559.
  10. Traynor K.: First quadrivalent flu vaccine approved. Am J Health Syst Pharm 2012; 69: 538.
  11. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphereinfluenza season. Weekly Epidemiological Record 2012; 87: 83-95.
  12. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2013-14 northern hemisphere influenza season. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/2013_14_north/en/.
  13. U.S. Food and Drug Administration 2007. Guidance for Industry: Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM091985.pdf.
  14. European Medicines Agency 2016. Guideline on Influenza Vaccines. Non-clinical and Clinical Module. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500211324.pdf.
  15. Pépin S., Donazzolo Y., Jambrecina A., Salamand C., Saville M.: Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine. 2013; 31: 5572-5578.
  16. Sesay S., Brzostek J., Meyer I. et al.: Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: a phase III randomized, double-blind clinical trial. Hum Vaccin Immunother. October 2017:0. doi:10.1080/21645515.2017.1384106.
  17. Ustawa z dnia 12 maja 2011 r. o refundacji leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych. (Dz.U. 2011 nr 122 poz. 696) Available from: http://isap.sejm.gov.pl/DetailsServlet?id=WDU20111220696.
  18. Chit A., Roiz J., Aballea S.: An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model. PLoS One. 2015; 10: e0133606.
  19. EuroMOMO. European monitoring of excess mortality for public health action. Available from: www.euromomo.eu.
  20. Schanzer D.L., Tam T.W., Langley J.M., Winchester B.T.: Influenza-attributable deaths, Canada 1990-1999. Epidemiol Infect 2007;135:1109-16.
  21. Thompson W.W., Shay D.K., Weintraub E. et al.: Influenza associated hospitalizations in the United States. JAMA 2004;292:1333-40.
  22. Ernst & Young 2013. Grypa i jej koszty. Wstępne studium w projekcie dotyczącym wypracowania rozwiązania na poziomie narodowym umożliwiającego istotne zwiększenie wyszczepialności przeciw grypie sezonowej w Polsce. Available from: http://opzg.cn-panel.pl/resources/dokumenty/dla-pracodawcow/Grypa-i-jej-koszty-w-Polsce.pdf.
  23. Opinia Rady Konsultacyjnej w sprawie przygotowania analizy zasadności finansowania ze środków publicznych profilaktycznych szczepień przeciw grypie sezonowej jako szczepień obowiązkowych w wybranych grupach ryzyka dla produktów leczniczych Agrippal, Fluarix, Influvac, Vaxigrip/Vaxigrip Junior, Infleksal V. Available from: http://wwwold.aotm.gov.pl/assets/files/rada/opinie/opinia9.pdf.
  24. Uhart M., Bricout H., Clay E., Largeron N.: Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe. Hum Vaccin Immunother. 2016; 12: 2259-68.
  25. Barbieri M., Patarnello F., Boccalini S. et al.: Quadrivalent versus trivalent influenza vaccine: Is it good value for money?. Value Health 2013; 16(7):A357
Cytowane przez
Pokaż
ISSN
2299-1247
Język
eng
URI / DOI
http://dx.doi.org/10.7365/JHPOR.2018.1.3
Udostępnij na Facebooku Udostępnij na Twitterze Udostępnij na Google+ Udostępnij na Pinterest Udostępnij na LinkedIn Wyślij znajomemu